<VariationArchive VariationID="223195" VariationName="NM_198156.3(VHL):c.341-3273del" VariationType="Deletion" Accession="VCV000223195" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2016-03-09" MostRecentSubmission="2016-03-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="224927" VariationID="223195">
      <GeneList>
        <Gene Symbol="LOC107303340" FullName="3p25 von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase Alu-mediated recombination region" GeneID="107303340" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10142339" stop="10160352" display_start="10142339" display_stop="10160352" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="VHL" FullName="von Hippel-Lindau tumor suppressor" GeneID="7428" HGNC_ID="HGNC:12687" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10141778" stop="10153667" display_start="10141778" display_stop="10153667" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183318" stop="10195353" display_start="10183318" display_stop="10195353" Strand="+" />
          </Location>
          <OMIM>608537</OMIM>
          <Haploinsufficiency last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_198156.3(VHL):c.341-3273del</Name>
      <CanonicalSPDI>NC_000003.12:10146512:GG:G</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10146513" stop="10146513" display_start="10146513" display_stop="10146513" variantLength="1" positionVCF="10146512" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10188197" stop="10188197" display_start="10188197" display_stop="10188197" variantLength="1" positionVCF="10188196" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10188198del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10188198del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.10146514del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.10146514del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008212.3" sequenceAccession="NG_008212" sequenceVersion="3" change="g.9880del">
            <Expression>NG_008212.3:g.9880del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046756.1" sequenceAccession="NG_046756" sequenceVersion="1" change="g.4276del">
            <Expression>NG_046756.1:g.4276del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354723.2" sequenceAccession="NM_001354723" sequenceVersion="2" change="c.*18-3273del">
            <Expression>NM_001354723.2:c.*18-3273del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_198156.3" sequenceAccession="NM_198156" sequenceVersion="3" change="c.341-3273del">
            <Expression>NM_198156.3:c.341-3273del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_322" sequenceAccession="LRG_322">
            <Expression>LRG_322:g.9880del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_322t1" sequenceAccession="LRG_322t1">
            <Expression>LRG_322t1:c.341del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA357071" DB="ClinGen" />
        <XRef Type="rs" ID="869025638" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_198156.3(VHL):c.341-3273del AND Von Hippel-Lindau syndrome" Accession="RCV000208824" Version="10">
        <ClassifiedConditionList TraitSetID="570">
          <ClassifiedCondition DB="MedGen" ID="C0019562">Von Hippel-Lindau syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2016-02-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-02-26" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-03-09" MostRecentSubmission="2016-03-09">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="570" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6116" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Von Hippel-Lindau syndrome</ElementValue>
                <XRef ID="Von+Hippel-Lindau+syndrome/7416" DB="Genetic Alliance" />
                <XRef ID="46659004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VHL syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Hippel-Lindau</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VHLS</ElementValue>
                <XRef Type="MIM" ID="193300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.</Attribute>
                <XRef ID="NBK1463" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7855" />
                <XRef ID="7855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552165" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569658" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000314230" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301636</ID>
                <ID Source="BookShelf">NBK1463</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Von Hippel-Lindau">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome</URL>
                <CitationText>PDQ® Cancer Genetics Editorial Board. PDQ Von Hippel-Lindau Disease. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="892" DB="Orphanet" />
              <XRef ID="C0019562" DB="MedGen" />
              <XRef ID="MONDO:0008667" DB="MONDO" />
              <XRef Type="MIM" ID="193300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="495423" SubmissionDate="2016-03-02" DateLastUpdated="2016-03-09" DateCreated="2016-03-09">
        <ClinVarSubmissionID localKey="VHL_55|OMIM:193300" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000264719" DateUpdated="2016-03-09" DateCreated="2016-03-09" Type="SCV" Version="1" SubmitterName="Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia" OrgID="165021" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-02-26">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>somatic</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VHL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.[Gly114Valfs*45]</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000551.3:c.341delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="193300" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>VHL</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="495423" TraitType="Disease" MappingType="XRef" MappingValue="193300" MappingRef="OMIM">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

